James J Harding, MD - Memorial Sloan Kettering Cancer Center - Assistant Attending

James J Harding

MD

Memorial Sloan Kettering Cancer Center

Assistant Attending

United States

Main Specialties: Hematology & Oncology

Additional Specialties: Medical Oncology

James J Harding, MD - Memorial Sloan Kettering Cancer Center - Assistant Attending

James J Harding

MD

Introduction

Dr. James Harding is a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York, USA. He specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer. His primary goal is to provide the best possible treatment and individualized care for people with these diseases. In his research, he is trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, he is working on ways to use a patient’s own immune system to fight cancer. In addition, Dr. Harding is investigating strategies to block specific cellular pathways that cancer uses to grow. He has helped develop and lead numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors. Dr. Harding’s research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute.

Primary Affiliation: Memorial Sloan Kettering Cancer Center - United States

Specialties:

Additional Specialties:

Research Interests:

Education

Jul 2013
Memorial Sloan Kettering Cancer Center
Hematology and Oncology
Jul 2010
New York Presbyterian Hospital
Internal Medicine

Publications

46Publications

1971Reads

28Profile Views

Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?

Dig Dis Sci 2019 04;64(4):918-927

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-019-05517-6DOI Listing
April 2019
2 Reads
2.550 Impact Factor

Understanding and quantifying the immune microenvironment in hepatocellular carcinoma.

Transl Gastroenterol Hepatol 2018 24;3:107. Epub 2018 Dec 24.

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://tgh.amegroups.com/article/view/4791/html
Publisher Site
http://dx.doi.org/10.21037/tgh.2018.12.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327173PMC
December 2018
3 Reads

Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.

Authors:
James J Harding

Future Oncol 2018 Sep 17;14(22):2293-2302. Epub 2018 Apr 17.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0008DOI Listing
September 2018
8 Reads
2.480 Impact Factor

Learning All That We Can From MyPathway.

J Clin Oncol 2018 08 1;36(23):2450-2451. Epub 2018 Jun 1.

Jessica J. Tao, Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY; and James J. Harding, Alexander Drilon, and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.4728DOI Listing
August 2018
13 Reads
18.430 Impact Factor

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

BMC Cancer 2018 Jun 27;18(1):693. Epub 2018 Jun 27.

David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4605-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020418PMC
June 2018
65 Reads
3.362 Impact Factor

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine.

Radiology 2018 05 31;287(2):667-675. Epub 2018 Jan 31.

From the Department of Radiology (M.P.S.D., W.W., J.S.L.), Department of Medicine (J.J.H., J.B., A.M.O., J.J.H., I.K.M., J.F.G., D.P.K.), Radiochemistry and Molecular Imaging Probe Core (H.Z., E.M.B., S.K.L., J.S.L.), and Department of Medical Physics (B.J.B., P.B.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room S113E, New York, NY 10065; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY (H.Z., K.S., J.S.L.); Department of Radiology, Weill-Cornell Medical College, New York, NY (M.P.S.D., W.W., J.S.L.); Laboratory of Neural Systems, the Rockefeller University, New York, NY (C.P.); Department of Pathology, University of Michigan, Ann Arbor, Mich (S.V.); and Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, Pa (H.F.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017162610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929369PMC
May 2018
39 Reads
6.870 Impact Factor

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017
102 Reads

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017
157 Reads
27.363 Impact Factor

Hepatocellular carcinoma in patients with HIV.

Curr Opin HIV AIDS 2017 01;12(1):20-25

aMemorial Sloan Kettering Cancer Center bWeill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COH.0000000000000335DOI Listing
January 2017
34 Reads
4.680 Impact Factor

Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Chin Clin Oncol 2016 Oct;5(5):66

Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2016.10.02DOI Listing
October 2016
19 Reads

Advanced Hepatocellular Cancer: the Current State of Future Research.

Curr Treat Options Oncol 2016 08;17(8):43

Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-016-0415-3DOI Listing
August 2016
8 Reads

Acute myeloid leukemia masquerading as hepatocellular carcinoma.

J Gastrointest Oncol 2016 Jun;7(3):E31-5

1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; 2 Department of Medicine, Weill Cornell Medical College, New York, NY, USA ; 3 Departments of Pathology and Laboratory Medicine, 4 Department of Radiology, 5 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; 6 Department of Surgery, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2015.12.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880775PMC
June 2016
31 Reads

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Cancer 2016 Feb 5;122(3):367-77. Epub 2015 Nov 5.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29769DOI Listing
February 2016
40 Reads
4.890 Impact Factor

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Oncologist 2015 Jul 8;20(7):789-97. Epub 2015 May 8.

Departments of Medicine and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA; Human Oncology and Pathogenesis Program, Memorial Hospital Research Laboratories, New York, New York, USA; Immunology and Molecular and Pharmacology and Chemistry Programs, Sloan Kettering Institute, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492223PMC
July 2015
68 Reads
4.870 Impact Factor

Treating advanced hepatocellular carcinoma: How to get out of first gear.

Cancer 2014 Oct 4;120(20):3122-30. Epub 2014 Jun 4.

Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28850DOI Listing
October 2014
24 Reads
4.890 Impact Factor

Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?

Hepatobiliary Surg Nutr 2014 Aug;3(4):168-71

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3881.2014.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141298PMC
August 2014
17 Reads

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

J Clin Oncol 2014 May 27;32(14):e54-6. Epub 2014 Jan 27.

Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.3528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879708PMC
May 2014
19 Reads
18.430 Impact Factor

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Cancer Discov 2014 May 3;4(5):538-45. Epub 2014 Mar 3.

1Human Oncology and Pathogenesis Program, 2Leukemia Service, 3Gastrointestinal Oncology Service, 4Melanoma and Immunotherapeutics Service, Department of Medicine, 5Molecular Diagnostics Service, Department of Pathology, 6Department of Radiology, 7Center for Molecular Oncology, 8Ludwig Center for Cancer Immunotherapy, and 9Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center; and 10Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850735PMC
May 2014
48 Reads
15.930 Impact Factor

Systemic therapy for hepatocellular carcinoma.

Chin Clin Oncol 2013 Dec;2(4):37

Weill Medical College at Cornell University, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2013.07.06DOI Listing
December 2013
19 Reads

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

N Engl J Med 2012 Dec 7;367(24):2316-21. Epub 2012 Nov 7.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1208958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627494PMC
December 2012
52 Reads
55.873 Impact Factor

Vemurafenib sensitivity skin reaction after ipilimumab.

N Engl J Med 2012 Mar;366(9):866-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1114329DOI Listing
March 2012
9 Reads
55.873 Impact Factor

Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels.

Mol Immunol 2011 May 31;48(9-10):1160-7. Epub 2011 Mar 31.

Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2011.02.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086682PMC
May 2011
11 Reads
2.973 Impact Factor

Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation.

J Immunol 2006 Mar;176(6):3536-47

Department of Pediatrics, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.176.6.3536DOI Listing
March 2006
19 Reads
4.922 Impact Factor

Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.

Immunol Rev 2005 Oct;207:242-60

Division of Pediatric Immunology and Transplantation Biology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.0105-2896.2005.00306.xDOI Listing
October 2005
32 Reads
10.120 Impact Factor

Selective developmental defects of cord blood antigen-presenting cell subsets.

Hum Immunol 2004 Nov;65(11):1356-69

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305-5164, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2004.09.011DOI Listing
November 2004
26 Reads
2.140 Impact Factor

Top co-authors

Ghassan K Abou-Alfa
Ghassan K Abou-Alfa

American University of Beirut

21
David B Solit
David B Solit

Vanderbilt University School of Medicine

11
David M Hyman
David M Hyman

National Cancer Institute

10
Michael F Berger
Michael F Berger

Brigham and Women's Hospital and Harvard Medical School

9
Paul B Chapman
Paul B Chapman

Sloan-Kettering Institute

8
Ahmet Zehir
Ahmet Zehir

Tulane University

6
Maeve A Lowery
Maeve A Lowery

Memorial Sloan-Kettering Cancer Center

6
David S Klimstra
David S Klimstra

Memorial Sloan Kettering Cancer Center

5
Michael A Postow
Michael A Postow

Weill-Cornell Medical College

5